ANORMED BOARD RECOMMENDS SHAREHOLDERS ACCEPT MILLENNIUM OFFER

AnorMED Inc. ("AnorMED" or the "Company") announced that its Board of Directors has recommended that AnorMED shareholders accept and tender their shares to the offer by Millennium Pharmaceuticals, Inc., filed with applicable securities regulators and being mailed to shareholders, to purchase all of the outstanding common shares of AnorMED including all common shares issuable on the exercise of outstanding stock options, for US$12.00 per share in cash. The Millennium offer expires on November 10, 2006. Drug Newswire (http://www.drugnewswire.com/6824/)